DJIA 17,164.95 -251.90 -1.45%
NASDAQ 4,635.24 -48.17 -1.03%
S&P 500 1,994.99 -26.26 -1.30%
market minute promo

Express Scripts (NASDAQ: ESRX)

company name or ticker
Company Photos
(Click to zoom)

1 Amazing Chart Shows Why Gilead Sciences, Inc.'s Stock Still Belongs in Your Portfolio

Gilead Sciences saw its shares drop by close to 20% after its chief competitor, AbbVie, delivered a major blow to its hepatitis C franchise. A single chart, though, shows why selling this top biotech stock is probably a huge mistake.

Gilead Sciences, Inc. Fires Back at AbbVie Inc.

Gilead Sciences has cut a deal with CVS Health in response to AbbVie's Express Scripts agreement.

ETF Outlook: Guggenheim S&P Equal Weight Health Care ETF (RYH)

The Biggest Surprise in the Battle Between AbbVie and Gilead Sciences

AbbVie and Gilead Sciences continue their hep-C duel. Here's what is most surprising so far.

Gilead Sciences' New Contract Exclusivity Helps The Shares Advance

My Portfolio Of Well-Valued Growth Stocks

2015 Biotech Stock Preview: Rhythms Of The 'PermaBull'

Gilead Strikes Deal with CVS, Hits Back AbbVie

Cramer: Gilead 'Back in the Driver's Seat' After CVS Deal

Is Express Scripts Setting A Dangerous Precedent?

See More Articles...